Basit öğe kaydını göster

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

dc.contributor.authorSpigel, David
dc.contributor.authorUslu, Ruchan
dc.contributor.authorKrzakowski, Maciej
dc.contributor.authorLee, Jong-Seok
dc.contributor.authorCalabro, Luana
dc.contributor.authorFrontera, Osvaldo Aren
dc.contributor.authorXiong, Huiling
dc.contributor.authorBajars, Marcis
dc.contributor.authorRuisi, Mary
dc.contributor.authorBarlesi, Fabrice
dc.contributor.authorPark, Keunchil
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorVansteenkiste, Johan
dc.contributor.authorYang, James C. H.
dc.contributor.authorIshii, Hidenobu
dc.contributor.authorGarassino, Marina
dc.contributor.authorde Marinis, Filippo
dc.contributor.authorSzczesna, Aleksandra
dc.contributor.authorPolychronis, Andreas
dc.date.accessioned2021-12-10T13:04:07Z
dc.date.available2021-12-10T13:04:07Z
dc.date.issued2021
dc.identifier.citationPark K., ÖZGÜROĞLU M., Vansteenkiste J., Spigel D., Yang J. C. H. , Ishii H., Garassino M., de Marinis F., Szczesna A., Polychronis A., et al., "Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial", JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.8, ss.1369-1378, 2021
dc.identifier.issn1556-0864
dc.identifier.othervv_1032021
dc.identifier.otherav_ebd00947-a9a9-49a3-9d51-d7f483356c43
dc.identifier.urihttp://hdl.handle.net/20.500.12627/175331
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2021.03.009
dc.description.abstractIntroduction: In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectSOLUNUM SİSTEMİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectİç Hastalıkları
dc.subjectOncology
dc.subjectRespiratory Care
dc.subjectPulmonary and Respiratory Medicine
dc.subjectHealth Sciences
dc.titleAvelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial
dc.typeMakale
dc.relation.journalJOURNAL OF THORACIC ONCOLOGY
dc.contributor.departmentSungkyunkwan University (SKKU) , ,
dc.identifier.volume16
dc.identifier.issue8
dc.identifier.startpage1369
dc.identifier.endpage1378
dc.contributor.firstauthorID2717247


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster